FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression By Ogkologos - June 13, 2025 575 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LUMINOSITY study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Breast Cancer Survivor Opens Her Own Business 17 Years After Beating... February 25, 2021 Let’s Talk About Bubbles July 16, 2020 Neoadjuvant Docetaxel, Oxaliplatin, and S-1, as Part of Perioperative Chemotherapy, Prolongs... August 19, 2024 FDA Grants Accelerated Approval to Tovorafenib for Patients with Relapsed or... May 2, 2024 Load more HOT NEWS Today is Veterans Day Patient-Reported Outcomes Support the Overall Benefit of Trastuzumab Deruxtecan for Patients... Cancer waiting times: Latest updates and analysis Using Artificial Intelligence to Classify Lung Cancer Types, Predict Mutations
